{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Newsome SD"],"funding":["National Multiple Sclerosis Society"],"pagination":["1263-1274"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10480368"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(5)"],"pubmed_abstract":["Thyroid hormones are essential during developmental myelination and may play a direct role in remyelination and repair in the adult central nervous system by promoting the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes. Since tri-iodothyronine (T3) is believed to mediate the majority of important thyroid hormone actions, liothyronine (synthetic T3) has the potential to induce reparative mechanisms and limit neurodegeneration in multiple sclerosis (MS). We completed a phase 1b clinical trial to determine the safety and tolerability of ascending doses of liothyronine in individuals with relapsing and progressive MS. A total of 20 people with MS were enrolled in this single-center trial of oral liothyronine. Eighteen participants completed the 24-week study. O"],"journal":["Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"],"pubmed_title":["A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS."],"pmcid":["PMC10480368"],"funding_grant_id":["RG 5184A2/1"],"pubmed_authors":["Mowry EM","Shoemaker T","Tian F","Fiol J","Cooper DS","Mammen JSR","Fitzgerald KC","Cassard SD","Snoops S","Bhargava P","Newsome SD","Calabresi PA"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS.","description":"Thyroid hormones are essential during developmental myelination and may play a direct role in remyelination and repair in the adult central nervous system by promoting the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes. Since tri-iodothyronine (T3) is believed to mediate the majority of important thyroid hormone actions, liothyronine (synthetic T3) has the potential to induce reparative mechanisms and limit neurodegeneration in multiple sclerosis (MS). We completed a phase 1b clinical trial to determine the safety and tolerability of ascending doses of liothyronine in individuals with relapsing and progressive MS. A total of 20 people with MS were enrolled in this single-center trial of oral liothyronine. Eighteen participants completed the 24-week study. O","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-04-22T04:21:08.048Z","creation":"2024-12-04T07:34:11.646Z"},"accession":"S-EPMC10480368","cross_references":{"pubmed":["37460763"],"doi":["10.1007/s13311-023-01402-3"]}}